Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6271 AL 6285

[Gamma-secretase inhibitors and modulators]

Iwai A.

Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:83-7.

[Beta-secretase inhibitor]

Fukumoto H.

Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:88-92.

[Tau-targeted drugs for dementia]

Furukawa K.

Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:93-7.

ACS chemical neuroscience molecule spotlight on ELND006: another γ-secretase inhibitor fails in the clinic

Hopkins CR.

ACS Chem Neurosci. 2011 Jun 15;2(6):279-80. doi: 10.1021/cn2000469.

Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease

Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G.

Neurobiol Aging. 2011 May;32(5):763-77. doi: 10.1016/j.neurobiolaging.2009.04.016. Epub 2009 May 22.

Future targeted disease modifying drugs for Alzheimer's disease

Dash SK.

Recent Pat CNS Drug Discov. 2011 Jan;6(1):65-76. doi: 10.2174/157488911794079073.

Plasma concentration of donepezil to the therapeutic response of Alzheimer's disease in Taiwanese

Yang YH, Wu SL, Chou MC, Lai CL, Chen SH, Liu CK.

J Alzheimers Dis. 2011;23(3):391-7. doi: 10.3233/JAD-2010-100936.

The impact of cerebral amyloid angiopathy on the occurrence of cerebrovascular lesions in demented patients with Alzheimer features: a neuropathological study

De Reuck J, Deramecourt V, Cordonnier C, Leys D, Maurage CA, Pasquier F.

Eur J Neurol. 2011 Jun;18(6):913-8. doi: 10.1111/j.1468-1331.2010.03329.x. Epub 2011 Jan 18.

Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease

Ballard C, Corbett A, Sharp S.

Expert Rev Neurother. 2011 Mar;11(3):327-9. doi: 10.1586/ern.11.13.

[Prescription differences of dementia drugs in urban and rural areas in Germany]

Bohlken J, Selke GW, van den Bussche H.

Psychiatr Prax. 2011 Jul;38(5):232-6. doi: 10.1055/s-0030-1266020. Epub 2011 Mar 21.

Ginseng

Barton D.

Oncology (Williston Park). 2011 Apr;25(4 Suppl Nurse Ed):42-5.

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.

Expert Opin Ther Targets. 2011 Oct;15(10):1153-62. doi: 10.1517/14728222.2011.600691. Epub 2011 Jul 12.

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab

Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, Barakos J.

Alzheimers Dement. 2011 Jul;7(4):396-401. doi: 10.1016/j.jalz.2011.05.2353.

Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway

Andersen F, Viitanen M, Halvorsen DS, Straume B, Engstad TA.

BMC Geriatr. 2011 Oct 4;11:58. doi: 10.1186/1471-2318-11-58.

Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors

Tayeb HO, Yang HD, Price BH, Tarazi FI.

Pharmacol Ther. 2012 Apr;134(1):8-25. doi: 10.1016/j.pharmthera.2011.12.002. Epub 2011 Dec 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias